453 related articles for article (PubMed ID: 15682638)
1. Increasing tinea capitis prevalence in Stockholm reflects immigration.
Hällgren J; Petrini B; Wahlgren CF
Med Mycol; 2004 Dec; 42(6):505-9. PubMed ID: 15682638
[TBL] [Abstract][Full Text] [Related]
2. Pediatric tinea capitis caused by Trichophyton violaceum and Trichophyton soudanense in Rochester, Minnesota, United States.
Grigoryan KV; Tollefson MM; Olson MA; Newman CC
Int J Dermatol; 2019 Aug; 58(8):912-915. PubMed ID: 30548845
[TBL] [Abstract][Full Text] [Related]
3. A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China.
Deng S; Hu H; Abliz P; Wan Z; Wang A; Cheng W; Li R
Mycopathologia; 2011 Nov; 172(5):365-72. PubMed ID: 21701791
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes for tinea capitis in a skin of color population.
Bhanusali D; Coley M; Silverberg JI; Alexis A; Silverberg NB
J Drugs Dermatol; 2012 Jul; 11(7):852-6. PubMed ID: 22777228
[TBL] [Abstract][Full Text] [Related]
5. Continuous increase of Trichophyton tonsurans as a cause of tinea capitis in the urban area of Paris, France: a 5-year-long study.
Gits-Muselli M; Benderdouche M; Hamane S; Mingui A; Feuilhade de Chauvin M; Guigue N; Picat MQ; Bourrat E; Petit A; Bagot M; Alanio A; Bretagne S
Med Mycol; 2017 Jul; 55(5):476-484. PubMed ID: 27744309
[TBL] [Abstract][Full Text] [Related]
6. Tinea capitis in a paediatric population.
Hackett BC; O'Connell K; Cafferkey M; O'Donnell BF; Keane FM
Ir Med J; 2006; 99(10):294-5. PubMed ID: 17274169
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole.
Gupta AK; Adam P; Dlova N; Lynde CW; Hofstader S; Morar N; Aboobaker J; Summerbell RC
Pediatr Dermatol; 2001; 18(5):433-8. PubMed ID: 11737692
[TBL] [Abstract][Full Text] [Related]
8. Tinea capitis update: a continuing conflict with an old adversary.
Chen BK; Friedlander SF
Curr Opin Pediatr; 2001 Aug; 13(4):331-5. PubMed ID: 11717558
[TBL] [Abstract][Full Text] [Related]
9. Trichophyton violaceum: An Emerging Pathogen in Southern Switzerland.
Gaviria Morales E; Iorizzo M; Martinetti Lucchini G; Mainetti C
Dermatology; 2019; 235(5):434-439. PubMed ID: 31295740
[TBL] [Abstract][Full Text] [Related]
10. Tinea capitis dermatophytes: susceptibility to antifungal drugs tested in vitro and in vivo.
Mock M; Monod M; Baudraz-Rosselet F; Panizzon RG
Dermatology; 1998; 197(4):361-7. PubMed ID: 9873175
[TBL] [Abstract][Full Text] [Related]
11. Tinea capitis in adults.
Aste N; Pau M; Biggio P
Mycoses; 1996; 39(7-8):299-301. PubMed ID: 9009649
[TBL] [Abstract][Full Text] [Related]
12. Tinea capitis in adults in southern Spain. A 17-year epidemiological study.
Lova-Navarro M; Gómez-Moyano E; Martínez Pilar L; Fernandez-Ballesteros MD; Godoy-Díaz DJ; Vera-Casaño A; Crespo-Erchiga V
Rev Iberoam Micol; 2016; 33(2):110-3. PubMed ID: 26774593
[TBL] [Abstract][Full Text] [Related]
13. Isolation of Trichophyton violaceum and Trichophyton soudanense in Baltimore, Maryland.
Magill SS; Manfredi L; Swiderski A; Cohen B; Merz WG
J Clin Microbiol; 2007 Feb; 45(2):461-5. PubMed ID: 17151204
[TBL] [Abstract][Full Text] [Related]
14. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials.
Elewski BE; Cáceres HW; DeLeon L; El Shimy S; Hunter JA; Korotkiy N; Rachesky IJ; Sanchez-Bal V; Todd G; Wraith L; Cai B; Tavakkol A; Bakshi R; Nyirady J; Friedlander SF
J Am Acad Dermatol; 2008 Jul; 59(1):41-54. PubMed ID: 18378354
[TBL] [Abstract][Full Text] [Related]
15. Tinea capitis.
Gupta AK; Summerbell RC
Med Mycol; 2000 Aug; 38(4):255-87. PubMed ID: 10975696
[TBL] [Abstract][Full Text] [Related]
16. Systemic antifungal therapy for tinea capitis in children.
González U; Seaton T; Bergus G; Jacobson J; Martínez-Monzón C
Cochrane Database Syst Rev; 2007 Oct; (4):CD004685. PubMed ID: 17943825
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species.
Lipozencic J; Skerlev M; Orofino-Costa R; Zaitz VC; Horvath A; Chouela E; Romero G; Gourmala N; Paul C;
Br J Dermatol; 2002 May; 146(5):816-23. PubMed ID: 12000378
[TBL] [Abstract][Full Text] [Related]
18. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials.
Fleece D; Gaughan JP; Aronoff SC
Pediatrics; 2004 Nov; 114(5):1312-5. PubMed ID: 15520113
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of terbinafine for Tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2 and 4 weeks.
Filho ST; Cucé LC; Foss NT; Marques SA; Santamaria JR
J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):141-6. PubMed ID: 9784040
[TBL] [Abstract][Full Text] [Related]
20. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis.
Cáceres-Ríos H; Rueda M; Ballona R; Bustamante B
J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):80-4. PubMed ID: 10607324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
